Literature DB >> 10561691

Alternatively spliced isoforms of FE65 serve as neuron-specific and non-neuronal markers.

Q Hu1, M G Hearn, L W Jin, S L Bressler, G M Martin.   

Abstract

FE65 is predominantly expressed in brain and is especially rich in the regions with the highest densities of neurons. The FE65 protein binds to an intracellular domain of the beta-amyloid precursor protein (betaPP) and may modulate the production of beta-amyloid peptide (AP). One of FE65 exons, a mini-exon (exon 9, 6 bp), is alternatively spliced, giving rise to two isoforms varying only in 6 base pairs. We quantitated the two isoforms by a sensitive reverse transcription-competitive polymerase chain reaction technique, and characterized their expressions in various tissues and cell cultures, and the kinetics of expression of the two isoforms in P19 embryonal carcinoma cell lines during neuronal differentiation. Our results show that the exon 9-inclusive (E9) form, the more abundant form in brain, was exclusively expressed in neurons, while the exon 9-exclusive (DeltaE9) form was widely expressed in all non-neuronal cells, but was not expressed in differentiated neurons. When P19 cells were differentiated to neurons, expression of FE65 was significantly up regulated ( approximately 30-fold) and the splicing pattern of the FE65 pre-mRNA was switched from the DeltaE9 pattern to the E9 form. Based upon their distinctive expression patterns, these two isoforms may serve as neuronal and non-neuronal markers, and determination of their ratios may have applications in neuropathological diagnosis. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10561691     DOI: 10.1002/(sici)1097-4547(19991201)58:5<632::aid-jnr4>3.0.co;2-p

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  9 in total

1.  Computational analysis of candidate intron regulatory elements for tissue-specific alternative pre-mRNA splicing.

Authors:  M Brudno; M S Gelfand; S Spengler; M Zorn; I Dubchak; J G Conboy
Journal:  Nucleic Acids Res       Date:  2001-06-01       Impact factor: 16.971

2.  Alternatively spliced Robo2 isoforms in zebrafish and rat.

Authors:  Ertugrul Dalkic; Cem Kuscu; Ceren Sucularli; Iraz T Aydin; Kamil C Akcali; Ozlen Konu
Journal:  Dev Genes Evol       Date:  2006-04-20       Impact factor: 0.900

3.  A role for FE65 in controlling GnRH-1 neurogenesis.

Authors:  Paolo E Forni; Michele Fornaro; Suzanne Guénette; Susan Wray
Journal:  J Neurosci       Date:  2011-01-12       Impact factor: 6.167

4.  A novel function of the Fe65 neuronal adaptor in estrogen receptor action in breast cancer cells.

Authors:  Yuefeng Sun; Ravi Kasiappan; Jinfu Tang; Panida L Webb; Waise Quarni; Xiaohong Zhang; Wenlong Bai
Journal:  J Biol Chem       Date:  2014-03-11       Impact factor: 5.157

5.  FE65 in breast cancer and its clinicopathological significance.

Authors:  Junyao Xu; Erina Iwabuchi; Yasuhiro Miki; Ayako Kanai; Takanori Ishida; Hironobu Sasano
Journal:  Breast Cancer       Date:  2021-09-08       Impact factor: 4.239

6.  A flanking gene problem leads to the discovery of a Gprc5b splice variant predominantly expressed in C57Bl/6J mouse brain and in maturing neurons.

Authors:  Bethany H Cool; Guy C-K Chan; Lin Lee; Junko Oshima; George M Martin; Qubai Hu
Journal:  PLoS One       Date:  2010-04-26       Impact factor: 3.240

7.  Structural and functional characterization of a novel FE65 protein product up-regulated in cognitively impaired FE65 knockout mice.

Authors:  Bethany H Cool; Galynn Zitnik; George M Martin; Qubai Hu
Journal:  J Neurochem       Date:  2009-10-27       Impact factor: 5.372

8.  The amyloid precursor protein intracellular domain-fe65 multiprotein complexes: a challenge to the amyloid hypothesis for Alzheimer's disease?

Authors:  Daniel A Bórquez; Christian González-Billault
Journal:  Int J Alzheimers Dis       Date:  2012-02-09

Review 9.  APP Protein Family Signaling at the Synapse: Insights from Intracellular APP-Binding Proteins.

Authors:  Suzanne Guénette; Paul Strecker; Stefan Kins
Journal:  Front Mol Neurosci       Date:  2017-03-30       Impact factor: 5.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.